SGLT2 inhibitors and GLP-1 receptor agonists are emerging as effective treatments for HFpEF, a form of heart failure that has lacked good therapies.
~50% of HFHFpEF accounts for nearly half of all heart failure cases and has lacked effective treatments until recently
What the researchers found
SGLT2 inhibitors and GLP-1 receptor agonists show potential benefits in HFpEF management, alongside emerging AI-driven diagnostic and management tools.
Why it matters
HFpEF affects millions and has had no effective drug therapies until recently — SGLT2i and GLP-1 drugs could change this.
The numbers in context
HFpEF accounts for ~50% of all heart failure cases; no specific trial data reported in abstract.
How the study worked
Narrative review of HFpEF pathophysiology, pharmacological treatments, and technology-based management approaches.
Who was studied
Patients with heart failure with preserved ejection fraction
What this study cannot tell us
Narrative review — does not systematically assess evidence quality. AI tool benefits are largely theoretical or early-stage.
How to read the evidence
Narrative review — comprehensive overview but evidence quality varies across the discussed interventions.
When this study was published
Published in 2025, capturing the latest therapeutic and technological advances for HFpEF.
The bigger picture
The convergence of metabolic drugs and AI diagnostics could finally crack the HFpEF treatment problem that has frustrated cardiologists for decades.
Questions still open
- Which HFpEF phenotypes benefit most from GLP-1 drugs?
- Can AI tools identify HFpEF patients who will respond to specific treatments?
Common questions
What is HFpEF?
Can GLP-1 drugs help with heart failure?
Read the original research
Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.
Heart failure reviews, 31(1), 3
Citation
Pozzi, Andrea; Spoladore, Roberto; Iorio, Annamaria; Corrado, Giovanni; D'Amario, Domenico. (2025). Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.. Heart failure reviews, 31(1), 3. https://doi.org/10.1007/s10741-025-10585-0